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Abstract
Introduction The identification of patients at highest risk for
adverse outcome who are presenting with acute dyspnea to the
emergency department remains a challenge. This study
investigates the prognostic value of the newly described
midregional fragment of the pro-Adrenomedullin molecule (MR-
proADM) alone and combined to B-type natriuretic peptide
(BNP) or N-terminal proBNP (NT-proBNP) in patients with acute
dyspnea.
Methods We conducted a prospective, observational cohort
study in the emergency department of a University Hospital and
enrolled 287 unselected, consecutive patients (48% women,
median age 77 (range 68 to 83) years) with acute dyspnea.
Results MR-proADM levels were elevated in non-survivors (n =
77) compared to survivors (median 1.9 (1.2 to 3.2) nmol/L vs.
1.1 (0.8 to 1.6) nmol/L; P < 0.001). The areas under the receiver
operating characteristic curve (AUC) to predict 30-day mortality
were 0.81 (95% CI 0.73 to 0.90), 0.76 (95% CI 0.67 to 0.84)
and 0.63 (95% CI 0.53 to 0.74) for MR-proADM, NT-proBNP
and BNP, respectively (MRproADM vs. NTproBNP P = 0.38;
MRproADM vs. BNP P = 0.009). For one-year mortality the AUC
were 0.75 (95% CI 0.69 to 0.81), 0.75 (95% CI 0.68 to 0.81),
0.69 (95% CI 0.62 to 0.76) for MR-proADM, NT-proBNP and
BNP, respectively without any significant difference. Using
multivariate linear regression analysis, MR-proADM strongly
predicted one-year all-cause mortality independently of NT-
proBNP and BNP levels (OR = 10.46 (1.36 to 80.50), P = 0.02
and OR = 24.86 (3.87 to 159.80) P = 0.001, respectively).
Using quartile approaches, Kaplan-Meier curve analyses
demonstrated a stepwise increase in one-year all-cause
mortality with increasing plasma levels (P < 0.0001). Combined
levels of MR-proADM and NT-proBNP did risk stratify acute
dyspneic patients into a low (90% one-year survival rate),
intermediate (72 to 82% one-year survival rate) or high risk
group (52% one-year survival rate).
Conclusions MR-proADM alone or combined to NT-proBNP
has a potential to assist clinicians in risk stratifying patients
presenting with acute dyspnea regardless of the underlying
disease.
ADHF: acute decompensated heart failure; ADM: adrenomedullin; AECOPD: acute exacerbation of chronic obstructive pulmonary disease; AUC: 
area under the curve; BNP: B-type natriuretic peptide; CI: confidence interval; ED: emergency department; MR-proADM: midregional pro-adrenom-
edullin; NT-proBNP: n-terminal pro-B-type natriuretic peptide; ROC: receivers operating characteristic curves.Critical Care    Vol 13 No 4    Potocki et al.
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Introduction
Acute dyspnea is a frequent clinical presentation in the emer-
gency department (ED). Cardiac and pulmonary disorders
account for more than 75% of patients presenting with acute
dyspnea to the ED [1,2]. The identification of patients at high-
est risk for adverse outcomes with acute dyspnea remains a
challenge. Patient history and physical examination remain the
cornerstone of clinical evaluation [3], while disease-specific
scoring tools [4,5] and biomarkers such as natriuretic pep-
tides have been introduced to assist the clinician in the diag-
nostic and prognostic assessment [6-9].
Adrenomedullin (ADM) is a peptide of 52 amino acids and was
originally isolated from human pheochromocytoma cells and
has later been detected in other tissues, including heart, adre-
nal medulla, lungs, and kidneys [10,11]. It is a potent vasodila-
tor, causes hypotension and has inotropic and natriuretic
effects stimulated by cardiac pressure and volume overload
[12,13]. The midregional fragment of the pro-Adrenomedullin
molecule (MR-proADM), consisting of amino acids 24 to 71,
is more stable than ADM itself, is secreted in equimolar
amounts to ADM, and is easier to measure [14]. Elevated lev-
els of ADM have frequently been reported in patients with var-
ious diseases. In patients with sepsis, pneumonia, chronic
obstructive pulmonary disease, myocardial infarction, and
heart failure, MR-proADM levels were elevated and predicted
mortality [15-20]. In order to be relevant, a marker should pro-
vide prognostic information reflective of the wide spectrum of
diseases that might be present among patients with acute dys-
pnea. In clinical practice, the identification of dyspneic patients
at highest risk for adverse outcomes is an unmet clinical need.
Accordingly, in an effort to better understand the role of MR-
proADM in this setting, we tested the individual and combined
prognostic utility of MR-proADM together with established
prognostic predictors such as B-type natriuretic peptide
(BNP) or N-terminal proBNP (NT-proBNP).
Materials and methods
Study population
From April 2006 to March 2007, we prospectively enrolled
287 unselected, consecutive patients with acute dyspnea as
the most prominent symptom presenting to the ED of the Uni-
versity Hospital Basel, Switzerland. Patients under 18 years of
age, patients on hemodialysis and trauma patients were
excluded. The study was carried out according to the princi-
ples of the Declaration of Helsinki and approved by the local
ethics committee. Written informed consent was obtained
from all participating patients.
Clinical evaluation and follow-up
Patients underwent an initial clinical assessment including
clinical history, physical examination, echocardiogram, pulse
oximetry, blood tests including BNP, and chest X-ray.
Echocardiography and pulmonary function tests were per-
formed according to the treating physician.
Two independent internists reviewed all medical records
including BNP levels and independently classified the
patient's primary diagnosis into seven categories: acute
decompensated heart failure (ADHF), acute exacerbation of
chronic obstructive pulmonary disease (AECOPD), pneumo-
nia, acute complications of malignancy, acute pulmonary
embolism, hyperventilation, and others. In the event of diag-
nostic disagreement among the internist reviewers, they were
asked to meet to come to a common conclusion. In the event
that they were unable to come to a common conclusion, a
third-party internist adjudicator was asked to review the data
and determine which diagnosis was the most accurate.
The endpoint of the present study was defined as one-year all-
cause mortality. Each patient was contacted for follow-up, via
telephone, by a single trained researcher at specified intervals.
Regarding mortality data, referring physicians were contacted
or the administrative databases of respective hometowns
were reviewed, if necessary. Of note, one patient was lost to
follow-up, so mortality analyses were performed in 286
patients.
Laboratory measurements
Blood samples for determination of MR-proADM, BNP, and
NT-proBNP were collected at presentation into tubes contain-
ing potassium EDTA. Samples were frozen at -80°C until later
analysis. MR-proADM was detected with a sandwich immuno-
luminometric assay (MR-proADM, BRAHMS AG, Hen-
nigsdorf/Berlin, Germany), as described elsewhere [14].
Mean MR-proADM in 264 healthy individuals in previous inves-
tigations was 0.33 ± 0.07 nmol/L (range, 0.10–0.64 nmol/L)
and the assay has a measuring range from 0 to 100 nmol/L.
The limit of detection and limit of quantification were 0.05 and
0.23 nmol/L, respectively. The intra assay CV was 1.9% and
the inter laboratory CV was 9.8%. NT-proBNP levels were
determined by a quantitative electrochemiluminescence
immunoassay (Elecsys proBNP, Roche Diagnostics AG, Zug,
Switzerland) [21]. BNP was measured by a microparticle
enzyme immunoassay (AxSym, Abbott Laboratories, Abbott
Park/IL, USA) [22].
Statistical analysis
Continuous variables are presented as mean ± standard devi-
ation or median (with interquartile range), and categorical var-
iables as numbers and percentages. Univariate data on
demographic and clinical features were compared by Mann-
Whitney U test or Fisher's exact test as appropriate. Correla-
tions among continuous variables were assessed by the
Spearman rank-correlation coefficient. Plasma levels of MR-
proADM, NT-proBNP, and BNP were log-transformed to
achieve a normal distribution. Receivers operating characteris-
tic (ROC) curves were utilized to evaluate the accuracy of MR-
proADM, NT-proBNP, and BNP to predict death at one year
and areas under the curve (AUC) were calculated for all mark-
ers. AUCs were compared according to the method by HanleyAvailable online http://ccforum.com/content/13/4/R122
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Table 1
Patients' characteristics
Characteristic All patients
(n = 287)
Age, yearsa 77 (68 to 83)
Male gender (%) 52
Body mass index – kg/m2 b 26 ± 6
History (%)
Hypertension 68
History of heart failure 24
Coronary artery disease 28
Diabetes mellitus 18
Chronic obstructive pulmonary disease 34
Chronic kidney disease 28
Shortness of breath (%)
While walking up a slight incline (NYHA II) 20
While walking on level ground (NYHA III) 40
At rest (NYHA IV) 40
Physical examination findings (%)
Heart rate, bpmb 93 ± 23
Systolic blood pressure, mmHgb 138 ± 26
Diastolic blood pressure, mmHgb 83 ± 16
Respiratory ratea 24 (20 to 28)
Rales 54
Lower extremity edema 42
Hepatojugular reflux 8
Jugular venous distension 28
Oral chronic medication on admission (%)
Beta-blockers 39
Angiotensin-converting enzyme inhibitor/Angiotensin-II-receptor blockers 49
Loop diuretics 52
Calcium antagonists 18
Digoxin 5
Spironolactone 2
Laboratory findings
Serum creatinine, μmol/La 85 (66 to 120)
eGFR, mL/min/1.73 m2a 67 (44 to 89)
Blood urea nitrogen, mmol/La 7.3 (5.4 to 12.0)
Sodium, mmol/La 137 (134 to 139)
Hemoglobin, g/La 133 (118 to 145)
Troponin T, μg/La (n = 192) 0.01 (0.01 to 0.03)
BNP, pg/mLa 349 (90 to 1120)
NT-proBNP, pg/mLa 1656 (314 to 6105)
MR-proADM, nmol/La 1.2 (0.8 to 2.0)
Echocardiography findings (%) (n = 116)
Left ventricular ejection fractiona 56 (35 to 65)
a median (interquartile range), b means ± standard deviation.
BNP = B-type natriuretic peptide; eGRF = estimated glomerular filtration rate; MR-proADM = midregional pro-adrenomedullin; NT-proBNP = N-
terminal pro-B-type natriuretic peptide; NYHA = New York Heart Association.Critical Care    Vol 13 No 4    Potocki et al.
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and McNeil [23]. To identify independent predictors of out-
come, linear regression analysis was assessed by univariate
and multivariate analysis. Factors with univariate significance
of  P  < 0.1 were included in multivariate analysis. To test
whether higher MR-proADM levels in non-survivors are found
regardless of the underlying diagnosis, linear regression anal-
ysis for one-year mortality was performed to exclude the pos-
sibility of confounding. We considered the variables MR-
proADM and diagnosis in parallel in the same linear regression
model to look for interaction terms. The Kaplan-Meier cumula-
tive survival curves in which patients were divided into quar-
tiles of biomarker plasma levels were constructed and
compared by the log-rank test. Glomerular filtration rate was
calculated using the abbreviated Modification of Diet in Renal
Disease formula [24]. Data were statistically analyzed with
SPSS 15.0 software (SPSS Inc, Chicago, IL, USA) and the
MedCalc 9.3.9.0 package (MedCalc Software, Mariakerke,
Belgium). All probabilities were two tailed and P < 0.05 was
regarded as significant.
Results
Patient characteristics
The demographic features of the 287 acute dyspneic patients,
at admission in the ED, are shown in Table 1. The primary diag-
nosis was ADHF in 154 (54%) patients, AECOPD in 57
(20%) patients, pneumonia in 32 (11%) patients, acute pul-
monary embolism in 8 (3%) patients, acute complications of
malignancy in 7 (2%) patients, hyperventilation in 5 (2%)
patients, and other causes such as interstitial lung disease,
asthma, or bronchitis in 24 (8%) patients. Diuretics (52%)
were the most common oral chronic medications recorded at
admission, followed by angiotensin converting enzyme inhibi-
tors or angiotensin-receptor blockers (49%), and beta-block-
ers (39%).
MR-proADM levels at admission
The median plasma level of MR-proADM on admission was
1.2 nmol/L (0.8 to 2.0 nmol/L) in all patients. Levels were
higher in patients admitted with ADHF (1.6 (1.1 to 2.6) nmol/
L) than in patients with AECOPD (0.8 (0.6 to 1.1) nmol/L; P <
0.001) and pneumonia (1.2 (0.9 to 2.0) nmol/L; P = 0.015,
Figure 1).
Figure 1
Midregional pro-adrenomedullin concentrations at admission as a func- tion of diagnosis Midregional pro-adrenomedullin concentrations at admission as a func-
tion of diagnosis. ADHF = acute decompensated heart failure; 
AECOPD = acute exacerbation of chronic obstructive pulmonary dis-
ease; MR-proADM = midregional pro-adrenomedullin.
Figure 2
Midregional pro-adrenomedullin, N-terminal pro B-type natriuretic peptide and B-type natriuretic peptide concentrations at admission as a function of  survival at one year Midregional pro-adrenomedullin, N-terminal pro B-type natriuretic peptide and B-type natriuretic peptide concentrations at admission as a function of 
survival at one year. BNP = B-type natriuretic peptide; MR-proADM = midregional pro-adrenomedullin; NT-proBNP = N-terminal pro-B-type natriu-
retic peptide.Available online http://ccforum.com/content/13/4/R122
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In addition, plasma levels of MR-proADM were higher in
patients with a history of hypertension (P < 0.001), renal insuf-
ficiency (P < 0.001), coronary artery disease (P = 0.004), and
diabetes mellitus (P = 0.038) but similar between women and
men. Plasma MR-proADM on admission correlated with age
(rs = 0.51, P < 0.001), estimated glomerular filtration rate (rs =
-0.76, P < 0.001), BNP (rs = 0.63, P < 0.01), and NTproBNP
(rs = 0.75, P < 0.001), whereas only a weak correlation was
found with New York Heart Association class (rs = 0.29, P <
0.001).
Prediction of death by MR-proADM and natriuretic 
peptides
Seventy-seven patients (27%) reached the endpoint of one-
year all-cause mortality. Figure 2 illustrates that non-survivors
had higher MR-proADM levels with a median of 1.9 (1.2 to 3.2)
nmol/L than survivors with a median of 1.1 (0.8 to 1.6) nmol/L
(P < 0.001). The BNP and NT-proBNP levels were also higher
in non-survivors than in survivors (881 (258 to 2436) pg/mL
and 5803 (1608 to 17,908) pg/mL vs. 248 (73 to 803) pg/mL
and 1015 (213 to 3904) pg/mL; P < 0.001 for both). The pat-
tern of higher MR-proADM concentrations in non-survivors
versus survivors remained when analysis were repeated in
patients without (1.23 vs. 0.85 nmol/L; P = 0.001) or with
(2.30 vs. 1.30 nmol/L; P < 0.001) ADHF. To test whether
higher MR-proADM levels are found in non-survivors regard-
less of the underlying diagnosis, linear regression analysis for
one-year mortality was performed and showed no significant
interaction between MR-proADM levels and diagnosis.
The results of the ROC analysis are showed in Figure 3. The
AUC to predict 30- and 90-day mortality were 0.81 (95% con-
fidence interval (CI) 0.73 to 0.90) and 0.77 (95% CI 0.70 to
0.85) for MR-proADM, 0.76 (95% CI 0.67 to 0.84) and 0.75
(95% CI 0.67 to 0.82) for NT-proBNP and 0.63 (95% CI 0.53
to 0.74), and 0.64 (95% CI 0.56 to 0.73) for BNP. There was
a significant difference between the AUC for MR-proADM and
the AUC for BNP for 30-day (P = 0.009) and 90-day (P =
0.02) mortality. The ROC analysis for one-year mortality dem-
Figure 3
Area under the receiver-operating characteristic curve for midregional  pro-adrenomedullin, N-terminal pro B-type natriuretic peptide and B- type natriuretic peptide to predict 30-day and one-year mortality Area under the receiver-operating characteristic curve for midregional 
pro-adrenomedullin, N-terminal pro B-type natriuretic peptide and B-
type natriuretic peptide to predict 30-day and one-year mortality. AUC 
= area under the receiver-operating characteristic curve; BNP = B-type 
natriuretic peptide; MR-proADM = midregional pro-adrenomedullin; 
NT-proBNP = N-terminal pro-B-type natriuretic peptide.
Table 2
Logistic regression analysis for one-year all-cause mortality
Variable Odds ratio (95% CI) P value
MR-proADMa 38.64 (12.13 to 123.14) <0.001
NT-proBNPa 3.46 (2.29 to 5.28) <0.001
BNPa 3.04 (1.95 to 4.75) <0.001
Age 1.07 (1.04 to 1.11) <0.001
eGRFa 0.12 (0.04 to 0.33) <0.001
Diagnosis of ADHF 2.58 (1.48 to 4.51) 0.001
NYHA class 1.77 (1.23 to 2.57) 0.002
Arterial hypertension 1.28 (0.72 to 2.26) 0.40
Male gender 1.24 (0.73 to 2.10) 0.42
History of coronary artery disease 0.88 (0.49 to 1.58) 0.66
Diabetes mellitus 0.89 (0.45 to 1.78) 0.74
a log-transformed to achieve normal distribution.
ADHF = acute decompensated heart failure; BNP = B-type natriuretic peptide; CI = confidence interval; eGRF = estimated glomerular filtration 
rate; MR-proADM = midregional pro-adrenomedullin; NT-proBNP = N-terminal pro-B-type natriuretic peptide; NYHA = New York Heart 
Association.Critical Care    Vol 13 No 4    Potocki et al.
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onstrated an AUC for MR-proADM of 0.75 (95% CI 0.69 to
0.81), for NT-proBNP of 0.75 (95% CI 0.68 to 0.81) and for
BNP of 0.69 (95% CI 0.62 to 0.76). There was no significant
difference between the AUC of MR-proADM and NT-proBNP
(P = 0.91) or between MR-proADM and BNP (P = 0.21).
Incremental value of MR-proADM
Linear regression analysis showed that plasma levels of MR-
proADM, NT-proBNP, BNP, diagnosis of ADHF, New York
Heart Association class, age, and estimated glomerular filtra-
tion rate, all assessed on ED admission, were predictors of
one-year all-cause mortality (Table 2). The multivariate analysis
was conducted with two separate models, one including NT-
proBNP and the other including BNP. In the model with NT-
proBNP, only MR-proADM, NT-proBNP, and age remained
significant predictors with the highest odds ratio (OR) for MR-
proADM (OR = 10.46 (1.36 to 80.50), P = 0.02). In the model
with BNP, only MR-proADM (OR = 24.86 (3.87 to 159.80), P
= 0.001) and age independently predicted one-year all-cause
mortality in our acutely dyspneic patients (Table 3).
Kaplan-Meier curves showed a stepwise increase in one-year
all-cause mortality with increasing plasma levels of each of the
three biological markers measured at admission: MR-proADM,
NT-proBNP and BNP (P < 0.001 for all). Thus, one-year all-
cause mortality was seemingly different when each of the
three biomarkers was above or below the median value (MR-
proADM 1.2 nmol/mL; NT-proBNP 1656 pg/mL, and BNP
349 pg/mL; Figure 4).
The additional value of combining MR-proADM and NT-
proBNP to optimally risk stratify acutely dyspneic patients is
shown in Figure 5a. The level of high or low MR-proADM levels
(above or below the median) can better stratify patients with
either low or high NT-proBNP levels. Accordingly, combined
levels of MR-proADM and NT-proBNP did risk stratify acute
dyspneic patients into a low (90% one-year survival rate), inter-
mediate (72 to 82% one-year survival rate), or high risk group
(52% one-year survival rate; Figure 5a). By contrast, the prog-
nostic value of MR-proADM was only moderate in combination
with BNP (Figure 5b).
Discussion
This study investigated the prognostic potential of MR-
proADM in a cohort of unselected patients admitted with
acute dyspnea to the ED. The risk stratification of patients with
dyspnea admitted to the ED is of paramount importance. An
unmet clinical need is to risk stratify this patient population to
improve the patient care in the first days of hospitalization. In
our study, we found that MR-proADM is a new powerful prog-
nostic marker of death independent of natriuretic peptide lev-
els and regardless of the underlying diagnosis. Furthermore,
MR-proADM improved the risk stratification when added to
NT-proBNP or to BNP. The combination of MR-proADM and
NT-proBNP can best risk stratify acute dyspneic patients into
three groups with a low, intermediate, or high-risk of death at
one year.
The concept of a biomarker measurement on admission to pre-
dict outcome in a variety of diseases has already being stud-
ied. Several studies focused on selected patient cohorts with
a primary diagnosis of acute coronary syndrome, heart failure,
chronic obstructive pulmonary disease, or pulmonary embo-
lism [1,25-27]. Natriuretic peptides have been shown to pro-
vide excellent predictive information for patients with acute
coronary syndromes, heart failure, and also with sepsis [28-
30]. It has been reported that multimarker strategies including
natriuretic peptides, troponin, and inflammatory markers are
Table 3
Multivariable logistic regression analysis for one-year all-cause mortality
Model with NTproBNP Model with BNP
Variable Odds ratio
(95% CI)
P value Odds ratio
(95% CI)
P value
MR-proADMa 10.46 (1.36 to 80.50) 0.02 24.86 (3.87 to 159.80) 0.001
NT-proBNPa 2.90 (0.35 to 6.25) 0.006 - -
BNPa - - 1.90 (0.89 to 4.10) 0.10
Diagnosis of ADHF 0.44 (0.18 to 1.07) 0.07 0.59 (0.23 to 1.47) 0.26
NYHA class 1.48 (0.95 to 2.30) 0.08 1.35 (0.88 to 2.08) 0.17
Age 1.04 (1.01 to 1.08) 0.02 1.04 (1.01 to 1.08) 0.01
eGRFa 4.48 (0.90 to 22.30) 0.07 3.40 (0.72 to 16.04) 0.12
a log-transformed to achieve normal distribution.
ADHF = acute decompensated heart failure; BNP = B-type natriuretic peptide; CI = confidence interval; eGRF = estimated glomerular filtration 
rate; MR-proADM = midregional pro-adrenomedullin; NT-proBNP = N-terminal pro-B-type natriuretic peptide; NYHA = New York Heart 
Association.Available online http://ccforum.com/content/13/4/R122
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Figure 4
Kaplan-Meier survival curves according to quartiles of (a) midregional pro-adrenomedullin, (b) N-terminal pro B-type natriuretic peptide and (c) B- type natriuretic peptide Kaplan-Meier survival curves according to quartiles of (a) midregional pro-adrenomedullin, (b) N-terminal pro B-type natriuretic peptide and (c) B-
type natriuretic peptide. BNP = B-type natriuretic peptide; MR-proADM = midregional pro-adrenomedullin; NT-proBNP = N-terminal pro-B-type 
natriuretic peptide.Critical Care    Vol 13 No 4    Potocki et al.
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superior to single marker strategies [31,32]. However, little is
known about the typical ED population, such as the patient
group admitted with acute dyspnea. In clinical practice, the
identification of dyspneic patients at highest risk for adverse
outcomes remains difficult and largely depends on the under-
lying cause. Adding to this complexity is the fact that acute
dyspnea is often multifactorial and due to cardiac, pulmonary,
and inflammatory causes. Specific markers for heart and/or
coronary dysfunction may therefore not be ideal to predict the
outcome of patients with acute dyspnea in the ED.
Recently, a multimarker strategy (of up to five markers) in
patients presenting with acute dyspnea to the ED was sug-
gested [33,34]. These markers included natriuretic peptides,
troponin, C-reactive protein, interleukin family member ST2,
hemoglobin, and blood urea nitrogen. Both studies have found
an increased risk of death in relation to the number of elevated
biomarkers.
We hypothesized that MR-proADM could stratify the risk of
mortality in patients admitted with acute dyspnea. We found
that MR-proADM is a new powerful prognostic marker of
death independent of natriuretic peptide levels. Furthermore,
Figure 5
Combined Kaplan-Meier survival curves Combined Kaplan-Meier survival curves. (a) Combined Kaplan-Meier survival curves according to midregional pro-adrenomedullin (MR-proADM) 
and N-terminal pro B-type natriuretic peptide (NT-proBNP) values below (low) and above (high) the median. (b) Combined Kaplan-Meier survival 
curves according to MR-proADM and B-type natriuretic peptide (BNP) values below (low) and above (high) the median.Available online http://ccforum.com/content/13/4/R122
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we could show that MR-proADM is even superior to BNP in
predicting short-term mortality after 30 days. This is in line with
studies showing that ADM and the more stable MR-proADM
are independent predictors of prognosis in patients with vari-
ous diseases, such as acute myocardial infarction, heart fail-
ure, sepsis, chronic obstructive pulmonary disease, and
pneumonia [15-18]. Our study further showed the incremental
value of MR-proADM when added to NT-proBNP to risk strat-
ify our acutely dyspneic patients. Indeed, if NT-proBNP was
low and MR-proADM was high, the patients had to be classi-
fied into the intermediate-risk group instead of the low-risk
group. More strikingly, if NT-proBNP was high and MR-
proADM was low, patients were classified as intermediate risk
instead of high risk. Accordingly, MR-proADM helps in creat-
ing an intermediate layer in the risk stratification when com-
bined with NT-proBNP levels in acutely dyspneic patients.
However, an additive effect to risk stratify acutely dyspneic
patients was only moderate when MR-proADM was combined
with BNP.
MR-proADM release in acutely dyspneic patients is most likely
related to three possible mechanisms. First, volume overload
can activate ADM gene transcription [35] and overexpression
of ADM leads to a biologic activity similar to that of natriuretic
peptides causing vasodilatation, an increase in cardiac output
and induction of natiuresis/diuresis [36]. Second, bacterial
endotoxins and proinflammatory cytokines up-regulate ADM
gene expression in many tissues [37] in different forms of
infection such as pneumonia [15,38]. Third, the kidneys and
the lungs play a role in the clearance of ADM. It has been
reported that ADM concentrations in aortic blood samples are
slightly lower than in pulmonary artery blood samples during
selective catheterization [39]. Therefore, impaired removal of
circulating ADM in the pulmonary circulation resulting from
infection-associated lung injury may partly contribute to the
elevation of plasma ADM levels. In contrast, one study sug-
gested that ADM plasma levels in patients with severe lung
disease are more likely caused by a systemic production than
by a reduced pulmonary clearance [40]. Another possible fac-
tor for high ADM plasma levels is endothelial production of
ADM triggered by hypoxia [41].
In the present study, the main causes of acute dyspnea were
acute heart failure, AECOPD, and pneumonia. Therefore, the
above mentioned mechanisms of ADM release reflect the
broad spectrum of our acutely dyspneic patients and our find-
ings confirm that the ADM system may be a new powerful can-
didate for the prediction of adverse outcome in this patient
population.
There are several limitations to our study. First, data derived
from a single-center study always need to be replicated in
larger multi-center studies such as the international, multi-
center Biomarkers in ACute Heart failure (BACH) trial. How-
ever, our cohort is representative because patient characteris-
tics are comparable with multi-center studies of acute dyspnea
[1,42]. Second, we assessed all-cause mortality because
classification of death in clinical practice can sometimes be
difficult and unreliable [43]. However, exact numbers of all dif-
ferent causes of death could have provided more interesting
insights into the pathophysiologic role of the biomarkers.
Conclusions
In summary, our study suggests that MR-proADM alone or
combined with NT-proBNP has the potential to assist clini-
cians in risk stratifying patients presenting with acute dyspnea
regardless of the underlying disease. Indeed, these biomark-
ers might help emergency physicians to tailor the therapy in
view of the relative risk and allocate resources accordingly.
Tailored therapy in high-risk patients may include immediate
initiation of non-invasive ventilation, consultation of specialists,
admission to the intensive care unit, and early and frequent
post-discharge visits to prevent relapse and readmission.
Whether this risk stratification guided strategy might affect
outcome needs to be evaluated prospectively.
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